Inventor · disambiguated record
Goncalo Abecasis
Also filed as: ABECASIS GONCALO · ABECASIS GONCALO ROCHA
11 granted patents·26 pending applications·4 citations·filing 2001–2025
81Inventor score
Top patents by PatentIndex Score
37 records- 0184US11820982B2Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 21, 2023·1 cites·7 claims
- 0284US11674177B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jun 13, 2023·1 cites·10 claims
- 0381US12258627B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 0474US2024148774A1Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0574US2025170226A1Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) AgonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0673US8119348B2Compositions and methods for diagnosing and treating macular degenerationSWAROOP ANAND·Filed 2010·Granted Feb 21, 2012·2 cites·6 claims
- 0773US2024102013A1Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0872US2025250631A1Kelch Domain Containing 7B (KLHDC7B) Variants And Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 0970US11865134B2Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2022·Granted Jan 9, 2024·0 cites·3 claims
- 1069US2025017929A1Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1167US2025129371A1Treatment Of Macular Degeneration With Complement Factor D (CFD) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1266US12186378B2Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonistsREGENERON PHARMA·Filed 2022·Granted Jan 7, 2025·0 cites·10 claims
- 1363US12070460B2Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitorsREGENERON PHARMA·Filed 2022·Granted Aug 27, 2024·0 cites·8 claims
- 1463US11512309B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 29, 2022·0 cites·13 claims
- 1563US2022064735A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1662US11767526B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2020·Granted Sep 26, 2023·0 cites·11 claims
- 1760US2023025878A1Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1860US2023041060A1Treatment of Varicose Veins With Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) AgonistsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1958US2009203001A1Compositions and methods for diagnosing and treating macular degenerationUNIV MICHIGAN·Filed 2008·Application pending·0 cites
- 2057US12264366B2Genome-based methods for reducing cardiovascular riskREGENERON PHARMA·Filed 2020·Granted Apr 1, 2025·0 cites·7 claims
- 2157US2023074721A1Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2257US2020370119A1Synaptojanin 2 (SYNJ2) Variants And Uses ThereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2357US2023034093A1Treatment Of Cognitive Impairment With Alpha-N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 5 (ST6GALNAC5) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2456US11845989B2Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2020·Granted Dec 19, 2023·0 cites·4 claims
- 2556US2023192864A1Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2656US2025257406A1Genome-Based Methods For Reducing Cardiovascular RiskREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2756US2023023182A1Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2855US2023027007A1Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2953US2021300976A1Fascin-2 (FSCN2) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3051US2021371930A1Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3151US2014322712A1Diagnosis and treatment of macular degenerationUNIV MICHIGAN·Filed 2014·Application pending·0 cites
- 3251US2022177982A1Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment ThereofREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3350US2022089664A1Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3448US2012135884A1Compositions and methods for diagnosing and treating macular degenerationSWAROOP ANAND·Filed 2012·Application pending·0 cites
- 3546US2013266937A1Compositions and methods for diagnosing and treating macular degenerationSWAROOP ANAND·Filed 2013·Application pending·0 cites
- 3641US2004067871A1Genetic determinants for dermal inflammation and immunityFiled 2001·Application pending·0 cites
- 3739US2011046202A1Method for testing a subject thought to have or to be predisposed to asthmaMOFFAT MIRIAM FLEUR·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Goncalo Abecasis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →